-+ 0.00%
-+ 0.00%
-+ 0.00%
Medivir Wins Rare Pediatric Disease Designation for MIV-711
Share
Listen to the news
04:07 AM EST, 11/19/2026 (MT Newswires) -- The US Food and Drug Administration gave Medivir's (MVIR.ST) MIV-711 a rare pediatric disease designation to treat patients with osteogenesis imperfecta. The pharmaceutical company said Thursday that the new designation was secured after meeting the US FDA's criteria to classify osteogenesis imperfecta as a rare pediatric disease. Medivir can potentially secure a priority review voucher for a future US FDA marketing application for the selective cathepsin K inhibitor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending